Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012IS102 Principal Investigator Warlick, Erica
Phase Phase III
Age Group Adult Scope National
Secondary Protocol No. CLTR0310-301
Title HM2012-18 Phase III, multicenter, randomized, trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus Cytarabine and Daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML. (CLTR0310-301)
Objective -To confirm the efficacy of CPX-351 compared to "7+3" as first line therapy in elderly patients (60-75 years) with high risk (secondary) AML. The primary endpoint with be overall survival. -To confirm the safety of CPX-351.
Applicable Disease Sites Acute myeloid leukemia (AML)
Drugs Involved CPX-351
CYTARABINE (ARA-C, CYTOSINE ARABINOSIDE, CYTOSAR-U)
DAUNOMYCIN (DAUNORUBICIN, CERUBIDINE)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Erica Warlick Phone:612-625-5467
Email:ewarlick@umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on